(Q40331927)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7044593%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

review article

1 reference

title

The podophyllotoxin derivatives VP16-213 and VM26 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7044593%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

author name string

B F Issell

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7044593%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

publication date

1 January 1982

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7044593%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

9 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7044593%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7044593%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

page(s)

73-80

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7044593%20AND%20SRC:MED&resulttype=core&format=json

9 October 2019

issue

2-3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:7044593%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/bf00254525

9 October 2019

exact match

0 references

cites work

PTG, a new antineoplastic epipodophyllotoxin

1 reference

12 December 2020

Proceedings: 4'-Demethyl-epipodophyllotoxin-beta-D-thenylidene-glucoside (PTG) in the treatment of malignant intracranial neoplasms

1 reference

12 December 2020

Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213)

1 reference

12 December 2020

Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer

1 reference

12 December 2020

Epipodophyllotoxin VP 16213 in treatment of acute leukaemias, haematosarcomas, and solid tumours

1 reference

12 December 2020

Evaluation of VP-16-213 in malignant lymphoma and melanoma

1 reference

12 December 2020

A phase II study of oral VP-16-213 in non-seminomatous testicular cancer

1 reference

12 December 2020

Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213

1 reference

12 December 2020

cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice

1 reference

12 December 2020

Acute monoblastic leukemia: diagnosis and treatment of ten cases

1 reference

12 December 2020

Effect of VP-16-213 on the intracellular degradation of DNA in HeLa cells

1 reference

12 December 2020

Epipodophyllotoxin (VP-16-213) in mycosis fungoides: A report from the Scandinavian mycosis fungoides study group

1 reference

12 December 2020

Phase II evaluation of VP-16-213 (NSC-141540) and cytembena (NSC-104801) in patients with advanced breast cancer

1 reference

12 December 2020

PHASE I clinical trial of an oral solution of VP-16-213

1 reference

12 December 2020

VM 26 (4-demethyl-epipodophyllotoxin-beta-d-thenylidine glucoside) in the treatment of urinary bladder tumors

1 reference

12 December 2020

Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivatives

1 reference

12 December 2020

VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules

1 reference

12 December 2020

VP-16-213 chemotherapy for advanced squamous cell carcinoma and adenocarcinoma of the lung

1 reference

12 December 2020

Single-drug chemotherapy of bladder cancer with adriamycin, VM-26 or bleomycin. A phase II multicentric, co-operative study

1 reference

12 December 2020

The toxicity of massive dosis of VM26 (4-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside). A contribution to the therapy of advanced ovarian cancer (author's transl)

1 reference

12 December 2020

Phase I-II trial of VM-26 (NSC-122819) in the treatment of children with late-stage leukemia

1 reference

12 December 2020

Cis-dichlorodiammineplatinum (II) and VP 16–213 combination chemotherapy for non-small cell lung cancer

1 reference

12 December 2020

VP-16-213 therapy in patients with small-cell carcinoma of the lung after failure on combination chemotherapy

1 reference

12 December 2020

4′-Demethyl-epipodophyllotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of action

1 reference

12 December 2020

Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma

1 reference

12 December 2020

Etoposide (VP-16-213)

1 reference

12 December 2020

Use of VM-26 as a single agent in the treatment of renal carcinoma

1 reference

12 December 2020

VM-26, a new anticancer drug with effectiveness in malignant lymphoma: an Eastern Cooperative Oncology Group Study (EST 1474).

1 reference

12 December 2020

Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas

1 reference

12 December 2020

cis-Dichlorodiammineplatinum(II) and VP-16-213: an active induction regimen for small cell carcinoma of the lung

1 reference

12 December 2020

Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents

1 reference

12 December 2020

Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213

1 reference

12 December 2020

VP16-213 as a single agent in advanced testicular tumors

1 reference

12 December 2020

EPEG, a new antineoplastic epipodophyllotoxin

1 reference

12 December 2020

VP 16-213 in acute myelogenous leukaemia

1 reference

12 December 2020

Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors.

1 reference

12 December 2020

VM26 (NSC-122819): A clinical study in advanced cancer of the lung and ovary

1 reference

12 December 2020

Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells

1 reference

12 December 2020

A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213

1 reference

12 December 2020

Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-D-glucopyranoside)

1 reference

12 December 2020

Clinical study of the new podophyllotoxin derivative, 4'-demethylepipodophyllotoxin 9-(4,6-o-ethylidene- beta-D-glucopyranoside) (NSC-141540; VP-16-213), in solid tumors

1 reference

12 December 2020

Epipodophyllotoxin (VP 16-213) in the treatmetn of diffuse histiocytic lymphoma

1 reference

12 December 2020

Phase I trial of a new form of an oral administration of VP-16-213

1 reference

12 December 2020

Chemotherapy of small cell carcinoma of the lung with V. P. 16–213

1 reference

12 December 2020

Clinical screening of epipodophyllotoxin VM26 in malignant lymphomas and solid tumours

1 reference

12 December 2020

Evaluation of VP-16 and the combination of adriamycin and vincristine in advanced breast cancer

1 reference

12 December 2020

Treatment of small cell bronchogenic carcinoma with VM-26

1 reference

12 December 2020

Experience with 4'-demethylepipodo-phyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside); VM-26; NSC-122819 in the treatment of malignant lymphosis

1 reference

12 December 2020

VP-16–213 salvage therapy for refractory germinal neoplasms

1 reference

12 December 2020

Phase II clinical trial of VP-16-213 in ovarian cancer

1 reference

12 December 2020

Clinical investigation of a new podophyllum derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidene- -D-glucopyranoside) (NSC-122819), in patients with malignant lymphomas and solid tumors

1 reference

12 December 2020

Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study

1 reference

12 December 2020

VM-26 and cytosine arabinoside combination chemotherapy for initial induction failures in childhood lymphocytic leukemia

1 reference

12 December 2020

Phase II study of VM-26 in adult malignancies

1 reference

12 December 2020

Activity of the epipodophyllotoxin VP-16 in the treatment of combination chemotherapy-resistant non-Hodgkin lymphoma

1 reference

12 December 2020

VP-16-213 versus polychemotherapy in patients with advanced small cell lung cancer

1 reference

12 December 2020

Epipodophyllotoxin VM-26 in the treatment of childhood neuroblastoma

1 reference

12 December 2020

VM-26 as a second drug in the treatment of brain gliomas

1 reference

12 December 2020

Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts

1 reference

12 December 2020

4'-demethylepipodophyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside) (NSC-122819; VM-26) and 4'-demethylepipodophyllotoxin 9-(4.6-0-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213) in childhood cancer: preliminary observations

1 reference

12 December 2020

Phase II study of VM-26 in acute leukemia, neuroblastoma, and other refractory childhood malignancies: a report from the Children's Cancer Study Group

1 reference

12 December 2020

Pulmonary hyaline membrane disease occurring in the course of VM-26 therapy

1 reference

12 December 2020

Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213)

1 reference

12 December 2020

Clinical trial of VP 16--213 (NSC 141540) I.V. twice weekly in advanced neoplastic disease: a study by the Cancer and Leukemia Group B

1 reference

12 December 2020

Phase II trial of VM-26 in patients with metastatic malignant melanoma

1 reference

12 December 2020

Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group Study

1 reference

12 December 2020

Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer

1 reference

12 December 2020

VM-26 monochemotherapy trial in the treatment of recurrent supratentorial gliomas: preliminary report.

1 reference

12 December 2020

Phase II study of VP-16-213 in childhood malignant disease: a Children's Cancer Study Group Report

1 reference

12 December 2020

Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma: response and toxicity.

1 reference

12 December 2020

Combined VM-26 and cytosine arabinoside in treatment of refractory childhood lymphocytic leukemia

1 reference

12 December 2020